Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.

Original title: “Summit and Akeso sharpen case for ivonescimab with new Western data”

Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.

Original title: “Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on”

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

Original title: “Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study”

Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.

Original title: “6 companies hiring in Cambridge now”

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

Original title: “Crystalys nets $130M more to push gout drug through late-stage tests”

The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.

Original title: “Novartis scraps mid-stage radiopharma asset as Pluvicto soars”

Working at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened thinking and leadership.

Original title: “From Big Pharma to specialty: why moving closer to the patient changes everything”

As drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.

Original title: “AI data becomes sticking point in biopharma dealmaking”

With PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.

Original title: “Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity”

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Original title: “Agios scraps sickle cell drug”

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

Original title: “Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs”